Macular Degeneration Treatment Market Growth, Size & Share Analysis - Industry Report on Trends & Forecasts (2025 - 2030)

Macular Degeneration Treatment Market Analysis

The Macular Degeneration Treatment Market size is estimated at USD 16.79 billion in 2025, and is expected to reach USD 25.25 billion by 2030, at a CAGR of 8.51% during the forecast period (2025-2030).

The major factors contributing to the macular degeneration treatment market growth include the rising prevalence of retinal disorders and eye diseases such as age-related macular degeneration and diabetic retinopathy, the growing aging population, and the increase in investments in research and development. The increase in retinal disorders is projected to boost the demand for treatments, which, in turn, will fuel the macular degeneration treatment market growth. For instance, an article published in the JAMA Network Journal in January 2024, mentioned that age-related macular degeneration (AMD) is a major contributor to significant vision loss among the elderly, and it is projected to impact around 288 million individuals globally by 2040. Additionally, an article published in the Investigative Ophthalmology & Visual Science Journal in December 2023, mentioned that the global prevalence of diabetic retinopathy (DR) is expected to increase to 161 million individuals by 2045. Thus, the increasing burden of retinal disorders is anticipated to drive the demand for macular degeneration treatment, thus contributing to market growth.

The rise in research and development (R&D) and increased clinical trials focusing on improving eye health such as anti vegf injections significantly contribute to macular degeneration treatment market growth. For instance, in September 2024, the pharmaceutical company Kyowa Kirin started conducting a Phase-2 clinical trial to assess the potential benefits of an experimental eye drop named KHK4951 for individuals with wet age-related macular degeneration (AMD), also called neovascular age-related macular degeneration (nAMD). KHK4951 is an experimental formulation of tivozanib, a groundbreaking inhibitor of vascular endothelial growth factor receptors, commonly called anti-VEGF treatments. Additionally, in January 2023, Oculogenex and Forge Biologics formed a manufacturing partnership to aid in the progression of Oculogenex's gene therapy program aimed at treating dry macular degeneration (AMD) as it moves toward clinical trials. Thus, such clinical trials for developing innovative macular degeneration treatments are likely to drive market growth.

According to the above-mentioned factors such as the rising burden of retinal disorders such as AMD and diabetic retinopathy is likely to fuel the macular degeneration treatment market. However, the growing prevalence of off-label drug usage and the insufficient awareness about the disease are significant challenges to market growth.

Macular Degeneration Treatment Market Trends and Insights

Wet Age-Related Macular Degeneration is Anticipated to Hold the Largest Market Share, says this Market Forecast

Wet age-related macular degeneration segment is expected to account for a substantial market share of 92.85% over the forecast period. The market size values of this segment are anticipated to reach USD 21.0 billion by 2029.

This chronic eye condition leads to blurred vision or the appearance of a blind spot in central vision. It typically arises from blood vessels leaking fluid or blood into the macula. It is also known as advanced neovascular AMD.

The high burden of wet macular degeneration is expected to fuel the demand for treatments, driving the overall macular degeneration treatment market growth. For instance, an article published by UC Davis Health in January 2023 mentioned that wet age-related macular degeneration (AMD) affects around 2 million individuals across the United States, Europe, and Japan. Thus, the significant proportion of individuals affected by wet age-related macular degeneration is expected to contribute to this segment’s growth.

The increasing clinical trials conducted by the market leaders and players to develop innovative wet AMD treatments are likely to drive the segment growth. For instance, in October 2024, Ocular Therapeutix accelerated timelines for its SOL-1 Phase-3 registration clinical trial of Axpaxli aimed at treating wet age-related macular degeneration (AMD). The company anticipated that the study would be fully enrolled with all 300 patients randomized by the end of 2024, and topline results were expected to be available in the fourth quarter of 2025. Thus, such clinical research activities conducted by the market players are anticipated to fuel the segment growth.

Market players adopt various strategies, including new product introductions, partnerships, advancements, acquisitions, mergers, and expansions, to enhance their market share and products for eye care. For instance, in November 2024, Samsung Bioepis Co., Ltd. and Biogen Inc. received approval from the European Commission (EC) for OPUVIZ (SB15) 40 mg/mL solution for injection in a vial, which was approved for use in adult patients for the treatment of neovascular (wet) age-related macular degeneration (AMD). Additionally, in July 2024, Genentech, which is part of the Roche Group, reintroduced Susvimo (ranibizumab injection) 100 mg/mL for intravitreal administration through an ocular implant aimed at treating individuals in the United States with wet or neovascular age-related macular degeneration (AMD), following the conclusion of a voluntary recall. Such initiatives adopted by the key players to enhance product availability for macular degeneration treatments are expected to boost the segment growth.

Owing to the abovementioned factors such as the high prevalence of wet age-related macular degeneration, increasing clinical research activities, and rising product approvals, are expected to drive the segment's growth over the forecast period.

Late-stage AMD is Expected to Witness Significant Growth in the Intraocular Lens Market Over the Forecast Period

By stage of disease segment, the late-stage AMD is anticipated to capture the largest market share, with a CAGR of 8.44% during the forecast period from 2024 to 2029. This macular degeneration treatment industry report forecasts the late-stage AMD segment to achieve a value of USD 22.02 billion by 2029.

At the late stage of AMD, the damage to the macula is often irreversible, resulting in visual impairment. By this point, the light-sensitive cells in the macula have deteriorated significantly. People experiencing this stage typically suffer from ongoing central vision loss but still retain some sight. The growth of this market segment during the forecast period is fuelled by the rising incidence of late-stage AMD, alongside an increase in research efforts aimed at developing new treatments, devices, and medications.

The macular degeneration treatment market is segmented by type, stage of disease, treatment type, route of administration, and sales channel. By type, the market is segmented into dry age-related macular degeneration and wet age-related macular degeneration. By stage of disease, the market is segmented into early-stage AMD, intermediate-stage AMD, and late-stage AMD. By treatment type, the market is segmented into drugs, devices, and surgery. By route of administration, the market is segmented into intravenous route and intravitreal route. By sales channel, the market is segmented into ambulatory surgical centers, hospitals, and other sales channels. The other sales channels include online pharmacies and various third-party distributors, including pharmaceutical companies and wholesalers. Supplements such as vitamin C, E, and beta carotene are widely used for macular degeneration treatment.

North America Region is anticipated to Hold the Largest Market Share throughout the Forecast Period

The North American market is projected to secure a significant market share, as this macular degeneration treatment industry report estimates a value of USD 6.35 billion in 2024 and increasing to USD 9.30 billion by 2029. Several factors contributing to market growth in the North American region include the rising prevalence of the aging population and age-related macular degeneration, the presence of major market players, and increased research and development activities.

The significant prevalence of retinal disorders such as age-related macular degeneration is expected to boost the adoption of its treatment across the region. For instance, an article published in the JAMA Network Journal in January 2024, mentioned that around 20 million individuals in the United States are affected by age-related macular degeneration (AMD). Thus, such a high burden of AMD is anticipated to drive the demand for treatments, contributing to the region's market growth.

The rising clinical research activities by the research institute, such as the development of stem cell therapy and laser treatment as an emerging treatment, are likely to drive market growth. For instance, in October 2024, researchers from the National Eye Institute employed human stem cells to create a model for age-related macular degeneration (AMD). The researchers found that a protein known as a tissue inhibitor of metalloproteinases 3 (TIMP3) was produced in excess in individuals with AMD. TIMP3 suppresses the function of enzymes known as matrix metalloproteinases (MMPs), which play a crucial role in maintaining eye health. Thus, such studies to develop stem cells for the treatment of AMD is expected to fuel the market growth.

Companies active in the market and their increasing initiatives, including partnerships, acquisitions, and introducing and approving new products, enhance the market presence of advanced technological systems and drugs, which is expected to drive market growth. For instance, in August 2023, the United States Food and Drug Administration approved IZERVAY to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The drug achieved its primary endpoint in the two Phase III trials, GATHER1 and GATHER2, which were double-masked, sham-controlled, multicenter, and randomized. These studies included over 700 participants and aimed to assess the efficacy and safety of a monthly 2mg intravitreal injection of IZERVAY. Additionally, in March 2023, Biogen Canada Inc. introduced BYOOVIZ (ranibizumab injection), one of the initial biosimilars referencing LUCENTIS in Canada, aimed at treating severe eye conditions such as neovascular (wet) age-related macular degeneration (AMD), a condition that can result in swift vision loss. Such product launches and increasing clinical research activities by the market players are likely to drive market growth in the region.

Overall, according to the above-mentioned factors, like the high prevalence of retinal disorders and rising product approvals, are anticipated to contribute to the market growth in North America.

By geography, the global market is segmented into North America (United States, Canada, Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, Rest of Middle East and Africa), and South America (Brazil, Argentina, Rest of South America). The Middle East and Africa regions, particularly countries such as Gulf Cooperation Council (GCC) and South Africa, are experiencing rapid growth driven by the rising prevalence of age-related macular degeneration (AMD), advancements in treatment technologies, the increasing elderly population, and technology advancements in the region's healthcare infrastructure.